A significant sized upside is ahead for the company
Now that the mechanism of action has been heavily confirmed already by AGN and NYR pre clinical studies, NYR will be the only drug in the world completing phase 1 for both stroke and traumatic brain injury leading into phase 2 for both. 100 billion dollar plus market potential on both conditions and says a lot of what’s to come once the remaining GLP results are out shortly and they dose the first humans next quarter.
Looking forward to the updated webinar this week where the CEO is talking on non dilutive funding after phase 1 is completed.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.035(17.5%) |
Mkt cap ! $49.56M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 23.5¢ | 20.0¢ | $405.2K | 1.907M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31257 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 103993 | 4 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |